Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Monoisotopic mass
262.131742452
InChI
InChI=1S/C14H18N2O3/c1-5-7-8-10(3)14(9-6-2)11(17)15-13(19)16(4)12(14)18/h6,10H,2,5,9H2,1,3-4H3,(H,15,17,19)
InChI Key
InChIKey=NZXKDOXHBHYTKP-UHFFFAOYSA-N
IUPAC Name
5-(hex-3-yn-2-yl)-1-methyl-5-(prop-2-en-1-yl)-1,3-diazinane-2,4,6-trione
Traditional IUPAC Name
methohexital
SMILES
CCC#CC(C)C1(CC=C)C(=O)NC(=O)N(C)C1=O
pKa (strongest acidic)
8.73
Refractivity
71.51 m3·mol-1
Dược Lực Học :
Methohexital, a barbiturate, is used for the induction of anesthesia prior to the use of other general anesthetic agents and for induction of anesthesia for short surgical, diagnostic, or therapeutic procedures associated with minimal painful stimuli. Little analgesia is conferred by barbiturates; their use in the presence of pain may result in excitation.
Cơ Chế Tác Dụng :
An intravenous anesthetic with a short duration of action that may be used for induction of anesthesia. [PubChem]
Methohexital binds at a distinct binding site associated with a Cl- ionopore at the GABAA receptor, increasing the duration of time for which the Cl- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged.
Dược Động Học :
▧ Absorption :
The absolute bioavailability following rectal administration of methohexital is 17%.
▧ Protein binding :
73%
▧ Metabolism :
Metabolism occurs in the liver through demethylation and oxidation. Side-chain oxidation is the most important biotransformation involved in termination of biologic activity.
▧ Route of Elimination :
Excretion occurs via the kidneys through glomerular filtration.
▧ Half Life :
5.6 ± 2.7 minutes
Độc Tính :
The onset of toxicity following an overdose of intravenously administered methohexital will be within seconds of the infusion. If methohexital is administered rectally or is ingested, the onset of toxicity may be delayed. The manifestations of an ultrashort-acting barbiturate in overdose include central nervous system depression, respiratory depression, hypotension, loss of peripheral vascular resistance, and muscular hyperactivity ranging from twitching to convulsive-like movements. Other findings may include convulsions and allergic reactions. Following massive exposure to any barbiturate, pulmonary edema, circulatory collapse with loss of peripheral vascular tone, and cardiac arrest may occur.
Chỉ Định :
Methohexital is indicated for use as an intravenous anaesthetic. It has also been commonly used to induce deep sedation.
Tương Tác Thuốc :
-
Aminophylline
The barbiturate, methohexital, decreases the effect of aminophylline.
-
Betamethasone
The barbiturate, methohexital, may decrease the effect of the corticosteroid, betamethasone.
-
Clomifene
The enzyme inducer, methohexital, decreases the effect of the hormone agent, clomifene.
-
Conjugated Estrogens
The enzyme inducer, methohexital, decreases the effect of the hormone agent, conjugated estrogens.
-
Cyclosporine
The barbiturate, methohexital, increases the effect of cyclosporine.
-
Dexamethasone
The barbiturate, methohexital, may decrease the effect of the corticosteroid, dexamethasone.
-
Diethylstilbestrol
The enzyme inducer, methohexital, decreases the effect of the hormone agent, diethylstilbestrol.
-
Doxycycline
The anticonvulsant, methohexital, decreases the effect of doxycycline.
-
Estradiol
The enzyme inducer, methohexital, decreases the effect of the hormone agent, estradiol.
-
Ethinyl Estradiol
This product may cause a slight decrease of contraceptive effect
-
Felodipine
The barbiturate, methohexital, decreases the effect of felodipine.
-
Fludrocortisone
The barbiturate, methohexital, may decrease the effect of the corticosteroid, fludrocortisone.
-
Folic Acid
Folic acid decreases the effect of anticonvulsant, methohexital.
-
Gefitinib
The CYP3A4 inducer, methohexital, may decrease the serum concentration and therapeutic effects of gefitinib.
-
Griseofulvin
The barbiturate, methohexital, decreases the effect of griseofulvin.
-
Hydrocortisone
The barbiturate, methohexital, may decrease the effect of the corticosteroid, hydrocortisone.
-
Levonorgestrel
Phenobarbital decreases the effect of levonorgestrel
-
Medroxyprogesterone Acetate
The enzyme inducer, methohexital, decreases the effect of the hormone agent, medroxyprogesterone.
-
Megestrol acetate
The enzyme inducer, methohexital, decreases the effect of the hormone agent, megestrol.
-
Methadone
The barbiturate, methohexital, decreases the effect of methadone.
-
Metronidazole
The barbiturate, methohexital, decreases the effect of metronidazole.
-
Nifedipine
The barbiturate, methohexital, decreases the effect of the calcium channel blocker, nifedipine.
-
Norethindrone
This product may cause a slight decrease of contraceptive effect
-
Oxtriphylline
The barbiturate, methohexital, decreases the effect of oxtriphylline.
-
Prednisolone
The barbiturate, methohexital, may decrease the effect of the corticosteroid, prednisolone.
-
Prednisone
The barbiturate, methohexital, may decrease the effect of the corticosteroid, prednisone.
-
Quinidine
The anticonvulsant, methohexital, decreases the effect of quinidine.
-
Theophylline
The barbiturate, methohexital, decreases the effect of theophylline.
-
Triamcinolone
The barbiturate, methohexital, may decrease the effect of the corticosteroid, triamcinolone.
-
Trimipramine
The barbiturate, Methohexital, may increase the metabolism and clearance of Trimipramine. Monitor for changes in the therapeutics and adverse effects of Trimipramine if Methohexital is initiated, discontinued or dose changed. Dose adjustments of Trimipramine may be required.
-
Triprolidine
The CNS depressants, Triprolidine and Methohexital, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
-
Verapamil
Methohexital, a CYP3A4 inducer, may increase the serum concentration of Verapamil, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Verapamil if Methohexital is initiated, discontinued or dose changed.
-
Warfarin
Methohexital may decrease the serum concentration of warfarin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of warfarin if methohexital is initiated, discontinued or dose changed.
Liều Lượng & Cách Dùng :
Injection, powder, for solution - Intramuscular
Injection, powder, for solution - Intravenous
Tài Liệu Tham Khảo Thêm
National Drug Code Directory